| Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2–advanced breast cancer: phase 1 results M Maglakelidze, I Bulat, D Ryspayeva, BM Krastev, M Gogiladze, ... J Clin Oncol 39 (15_suppl), 1063, 2021 | 22 | 2021 |
| Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer D Ryspayeva, A Lyashenko, I Dosenko, O Kostryba, O Koshyk, ... JBUON 25 (1), 168-75, 2020 | 10 | 2020 |
| Are CD44⁺/CD24⁻ cells the assumed cancer stem cells in breast cancer? DE Ryspayeva, II Smolanka, AS Dudnichenko, AA Lyashenko, ... Experimental Oncology, 2017 | 9 | 2017 |
| Abstract CT107: A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU … M Maglakelidze, D Ryspayeva, I Bulat, Z Andric, I Nikolic, T Chawla, ... Cancer Research 81 (13_Supplement), CT107-CT107, 2021 | 7 | 2021 |
| HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced … M Maglakelidze, DE Ryspayeva, Z Andric, Z Petrovic, I Bulat, I Nikolic, ... Journal of Clinical Oncology 41 (4_suppl), 289-289, 2023 | 6 | 2023 |
| Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter? D Ryspayeva, V Halytskiy, N Kobyliak, I Dosenko, A Fedosov, ... Discover Oncology 13 (1), 43, 2022 | 6 | 2022 |
| Эффективность лазерной терапии для лечения больных ангинами ВП Малый, ЛЯ Васильева-Линецкая, ДЭ Рыспаева Матер.-й межд. научно-практ. конф.«Применение лазеров в медицине и биологии, 2-0, 1997 | 5 | 1997 |
| HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu … R Laeufle, M Maglakelidze, I Bulat, D Ryspayeva, A Zoran, T Chawla, ... Journal of Clinical Oncology 39 (15_suppl), e16065-e16065, 2021 | 4 | 2021 |
| Отдаленные осложнения лучевой терапии у больных со злокачественными новообразованиями ИА Крячок, ЕО Ульянченко, ТВ Кадникова, ИБ Титоренко, ЕМ Алексик, ... Клиническая онкология, 59-62, 2017 | 4 | 2017 |
| Динамика показателей иммунных комплексов в сыворотке и слюне у больных дифтерией на фоне лазеротерапии ДЭ Рыспаева, АК Полукчи, ВП Малый, ЖК Манина Материалы VI Российского съезда врачей - инфекционистов. Санкт-Петербург …, 2003 | 2 | 2003 |
| BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in … WS El-Deiry, SL Graff, CG Azzoli, DS Dizon, MA Fenton, WM Sikov, ... Journal of Clinical Oncology 41 (16_suppl), TPS3167-TPS3167, 2023 | 1 | 2023 |
| P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of … M Maglakelidze, D Ryspayenva, I Bulat, Z Andric, I Nikolic, T Chawla, ... Annals of Oncology 32, S154, 2021 | 1 | 2021 |
| Формирование факторов прогноза рака желудка ЕА Антонов, ДЭ Риспаева, НЮ Спиженко Евразийский онкологический журнал 6 (3-4), 690-696, 2018 | 1 | 2018 |
| Тhe expression of topoisomerase IIα as a prognostic marker in patients with primary breast cancer DE Ryspayeva, II Smolanka, OS Dudnichenko Problems of Uninterrupted Medical Training and Science 1 (24), 32-8, 2017 | 1 | 2017 |
| GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer. WS El-Deiry, K Huntington, A Louie, P Srinivasan, C Schorl, S Lu, ... Journal of Clinical Oncology 41 (16_suppl), e15138-e15138, 2023 | | 2023 |
| 74MO HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic … M Maglakelidze, D Ryspayeva, ZG Andric, Z Petrovic, IV Bulat, IV Nikolic, ... Annals of Oncology 33, S1460, 2022 | | 2022 |
| 141P Molecular landscape of hereditary breast cancer in Ukrainian women D Kozakov, S Livshun, V Guryanov, D Ryspayeva, A Matveieva, ... Annals of Oncology 33, S186, 2022 | | 2022 |
| Expression Changes of Some miRNAs Patterns (miR-124a, miR-137, miR-373) in Patients with Invasive Breast Cancer Before and After Neoadjuvant Chemotherapy R Dinara, H Volodymyr, I Mariia, D Tetyana, G Vitalyi | | 2021 |
| Оптимальна інтеграція інгібіторів CDK4/6 у лікування гормон-рецепторпозитивного метастатичного раку молочної залози ДЕ Риспаєва | | 2021 |
| Features of postmastomic syndrome in a patients with inflammatory breast cancer II Smolanka, AO Lyashenko, AD Loboda, DE Ryspaeva, OM Ivankova, ... Likars' ka sprava, 30-35, 2020 | | 2020 |
Ursula WiedermannMedical UNiversity ViennaVerified email at meduniwien.ac.at
